Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer

Taiki Masuda, Toshiaki Ishikawa, Kaoru Mogushi, Satoshi Okazaki, Megumi Ishiguro, Satoru Iida, Hiroshi Mizushima, Hiroshi Tanaka, Hiroyuki Uetake, Kenichi Sugihara

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


We aimed to identify a novel prognostic biomarker related to recurrence in stage II and III colorectal cancer (CRC) patients. Stage II and III CRC tissue mRNA expression was profiled using an Affymetrix Gene Chip, and copy number profiles of 125 patients were generated using an Affymetrix 250K Sty array. Genes showing both upregulated expression and copy number gains in cases involving recurrence were extracted as candidate biomarkers. The protein expression of the candidate gene was assessed using immunohistochemical staining of tissue from 161 patients. The relationship between protein expression and clinicopathological features was also examined. We identified 9 candidate genes related to recurrence of stage II and III CRC, whose mRNA expression was significantly higher in CRC than in normal tissue. Of these proteins, the S100 calcium-binding protein A2 (S100A2) has been observed in several human cancers. S100A2 protein overexpression in CRC cells was associated with significantly worse overall survival and relapse-free survival, indicating that S100A2 is an independent risk factor for stage II and III CRC recurrence. S100A2 overexpression in cancer cells could be a biomarker of poor prognosis in stage II and III CRC recurrence and a target for treatment of this disease.

Original languageEnglish
Pages (from-to)975-982
Number of pages8
JournalInternational journal of oncology
Issue number3
Publication statusPublished - 2016 Mar


  • Biomarker
  • Colorectal cancer
  • DNA copy number analysis
  • Gene expression analysis
  • Microarray
  • S100A2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer'. Together they form a unique fingerprint.

Cite this